Company Filing History:
Years Active: 2013
Title: Astrid Nagell: A Pioneer in Liver Disease Treatment
Introduction
Astrid Nagell, an innovative inventor based in Hamburg, Germany, has made significant contributions to the field of liver disease treatment. With a focus on improving the efficacy of treatments for conditions such as viral hepatitis, Nagell's work showcases the intersection of science and practical application in medicine.
Latest Patents
Nagell holds one patent for her groundbreaking invention titled "Amorphous Silibinin for the Treatment of Viral Hepatitis." This invention details a method for the preparation of amorphous silibinin, also known as silybin or silibin, derived from a milk thistle fruit extract. The innovative approach enhances the release rate and bioavailability of silibinin, making it particularly effective for treating or preventing liver diseases, specifically viral hepatitis B and C, in patients who are undergoing or have undergone liver transplantation. The formulation is designed for oral administration, further increasing its practicality.
Career Highlights
Currently, Astrid Nagell is associated with Euromed S.A., where she continues her research and development efforts in liver disease treatments. Her work not only highlights her inventiveness but also points to her commitment to improving patient outcomes through scientifically driven solutions.
Collaborations
Throughout her career, Nagell has had the opportunity to collaborate with esteemed colleagues, including Lucio C. Rovati and Aguirre Jaime Xiol. These collaborations have played a pivotal role in advancing her research and developing new methodologies for addressing liver health issues.
Conclusion
Astrid Nagell stands out as a notable inventor in the field of medicine, especially concerning liver disease treatment. Her patent on amorphous silibinin underscores her innovative spirit and dedication to improving healthcare solutions. As she continues her work at Euromed S.A., the impact of her inventions is expected to resonate within the pharmaceutical landscape for years to come.